Recursion Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $5,175 | $19,103 | $14,745 | $4,511 |
Gross Profit | -24,418 | -1,058 | -7,084 | -8,283 |
EBITDA | -141,207 | -147,568 | -182,806 | -165,343 |
EBIT | -162,250 | -171,417 | -202,137 | -178,294 |
Net Income | -162,253 | -171,897 | -202,487 | -178,906 |
Net Change In Cash | 5,175 | 19,103 | 14,745 | 4,511 |
Free Cash Flow | -117,603 | -79,568 | -133,789 | -117,078 |
Cash | 659,836 | 528,216 | 500,453 | 594,350 |
Basic Shares | 446,988 | 417,361 | 402,772 | 336,036 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $58,839 | $43,876 | $39,681 | $10,000 |
Gross Profit | 13,601 | 1,289 | -8,594 | 10,000 |
EBITDA | -426,722 | -307,629 | -233,971 | -174,370 |
EBIT | -463,216 | -332,031 | -245,727 | -182,775 |
Net Income | -463,661 | -328,066 | -239,421 | -178,074 |
Net Change In Cash | 58,839 | 43,876 | 39,681 | 10,000 |
Cost of Revenue | 28,182 | |||
Free Cash Flow | -372,869 | -300,332 | -120,883 | -198,412 |
Cash | 594,350 | 391,565 | 549,912 | 285,116 |
Basic Shares | 274,207 | 207,853 | 175,537 | 170,272 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.36 |
2025-06-30 | -$0.41 |
2025-03-31 | -$0.50 |
